PDS Biotechnology (PDSB)
Develops investigational immunotherapies for cancer and infectious diseases.
Something off on this page? Send us feedback.
Develops investigational molecularly targeted immunotherapies through the Versamune, PDS01ADC-combination, and Infectimune platforms. The single-segment company’s lead oncology programs include PDS0101/Versamune HPV and PDS01ADC.
Develops proprietary molecularly targeted immunotherapies through the Versamune, PDS01ADC-combination, and Infectimune platforms. Its clinical-stage portfolio includes PDS0101/Versamune HPV, PDS01ADC, and PDS0103/Versamune MUC1 in oncology, with Infectimune for infectious diseases. PDS0101 is the lead program and is in a Phase 3 pembrolizumab-combination trial for HPV16-positive recurrent/metastatic head-and-neck cancer. All cited programs remain investigational.
Operating as one centrally managed reportable segment from Princeton, New Jersey, the company is led by Frank Bedu-Addo. Its work includes clinical development and research collaborations; trial execution, financing, intellectual-property protection, and continued Nasdaq compliance shape the business.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.6M · Total debt $4.4M · Total assets $8.8M · Shareholders' equity −$3.6M
- Revenue
- $0
- Operating income
- −$6.5M
- Net income
- −$9.8M
No dividends on record.
| Institutions | 13.74% | 7.69M shares | |
|---|---|---|---|
| 53 holders · as of Jun 30, 2026 | |||
| Insiders | 23.49% | 13.15M shares | |
| 4 holders · as of Sep 21, 2026 | |||
| Other | 62.77% | 35.13M shares | |
| remainder | |||
55.97M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Patrick Soon-ShiongInsiderdirector, 10 percent owner | 23.24% | 13.01M | filed Sep 21, 2026 |
Vanguard Capital Management LLCInstitution | 3.04% | 1.70M | as of Jun 30, 2026 |
Colony Group, LLCInstitution | 1.15% | 642,177 | as of Jun 30, 2026 |
Quantinno Capital Management LPInstitution | 1.15% | 642,177 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.09% | 607,639 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- BioNTech (ADR)
HPV16 mRNA immunotherapy in pivotal HNSCC trial
- Inovio Pharmaceuticals
HPV16/18 DNA and IL-12 immunotherapy for high-risk OPSCC
- Precigen
HPV-associated-cancer immunotherapy in Phase 2 studies
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PDS Biotechnology | $0.8771 | −3.62% | $50.9M | — | — | — | — |
| BioNTech (ADR) | $100.64 | −0.23% | $25.34B | — | — | 8.4 | −60.7% |
| Inovio Pharmaceuticals | $1.26 | −2.33% | $89.1M | — | — | — | — |
| Precigen | $7.76 | −1.65% | $2.81B | — | 14.8 | 32.8 | +6,161.7% |
| Median | — | 14.8 | 20.6 | +3,050.5% |